One of the most effective treatments for metastases from thyroid cancer is a form of
radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and
destroy thyroid cancer cells that have spread to other parts of the body. In many cases this
treatment destroys the metastatic cells. However, in some patients it does not appear to
work completely. This study is designed to use a slightly different form of radioactive
iodine (called 124-I) which can precisely predict the amount of radiation that each
metastatic lesion will receive.
124-I was developed at Memorial Sloan-Kettering in the 1950s and has been used here and at
many other medical centers around the world for diagnostic studies. It has been found to be
very safe and effective at finding metastatic lesions. The high resolution of newer PET
scanners now allows us to carefully determine how much radiation each metastatic lesion will
receive. If 124-I can accurately predict which patients will not respond to 131-I treatments
we can then avoid exposing those patients to unnecessary radiation. For the rest of the
patients we can custom tailor the 131-I dose to destroy the metastatic lesions.
- Adult thyroid carcinoma patients who have had a total thyroidectomy, histology
confirmed by an MSKCC attending pathologist, and radioiodine remnant ablation.
- Adult thyroid carcinoma patients who have previously demonstrated radioiodine-avid
metastases and are about to undergo Thyrogen-assisted dosimetry at MSKCC.
- The patient and physician are planning to administer 131-I for therapy if persistent
radioiodine-avid metastases are present.
- Men and women of all races, ethnicities, and religious backgrounds are eligible.
- All subjects must have measurable disease, documented within the previous six months
by ultrasonography (US), MRI, or non-contrast CT scanning.
- Thyroid cancer patients who do not have metastases.
- Thyroid cancer patients who have not demonstrated that their metastases concentrate
- Patients who are under therapy for other active cancers.
- Anaplastic or Medullary thyroid carcinoma.
- Age less than 18 years.
- Patient who have received a therapeutic dose of radioiodine within the preceding nine
months will not be eligible.
- Patients who plan to withdraw from thyroid hormone prior to dosimetry.
- Patients who are pregnant.